Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1980 Jul;43(7):644–659. doi: 10.1136/jnnp.43.7.644

Controversies about the treatment of myasthenia gravis.

L P Rowland
PMCID: PMC490631  PMID: 7400825

Abstract

Clinicians treating patients with myasthenia gravis must choose cholinergic drugs, corticosteroids, immunosuppressive drugs, thymectomy, or plasmapheresis. Clinicians must decide the sequence or combination of these therapies and when to deem lack of improvement a sign for a different therapeutic approach. Because controlled trials have not been done to evaluate therapies that may require months or years before benefit is evident, controversy abounds.

Full text

PDF
646

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpert L. I., Papatestas A., Kark A., Osserman R. S., Osserman K. A histologic reappraisal of the thymus in myasthenia gravis. A correlative study of thymic pathology and response to thymectomy. Arch Pathol. 1971 Jan;91(1):55–61. [PubMed] [Google Scholar]
  2. Arts W. F., Oosterhuis H. J. Effect of prednisolone on neuromuscular blocking in mice in vivo. Neurology. 1975 Nov;25(11):1088–1090. doi: 10.1212/wnl.25.11.1088. [DOI] [PubMed] [Google Scholar]
  3. Behan P. O. Combined plasma exchange and immunosuppression in myasthenia gravis. Lancet. 1979 Oct 6;2(8145):741–742. doi: 10.1016/s0140-6736(79)90666-4. [DOI] [PubMed] [Google Scholar]
  4. Behan P. O., Shakir R. A., Simpson J. A., Burnett A. K., Allan T. L., Haase G. Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. Lancet. 1979 Sep 1;2(8140):438–440. doi: 10.1016/s0140-6736(79)91492-2. [DOI] [PubMed] [Google Scholar]
  5. Behan W. M., Behan P. O. Immune complexes in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1979 Jul;42(7):595–599. doi: 10.1136/jnnp.42.7.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bergström K., Franksson C., Matell G., Nilsson B. Y., Persson A., von Reis G., Stensman R. Drainage of thoracic duct lymph in twelve patients with myasthenia gravis. Eur Neurol. 1975;13(1):19–30. doi: 10.1159/000114659. [DOI] [PubMed] [Google Scholar]
  7. Bergström K., Franksson C., Matell G., von Reis G. The effect of thoracic duct lymph drainage in myasthenia gravis. Eur Neurol. 1973;9(3):157–167. doi: 10.1159/000114221. [DOI] [PubMed] [Google Scholar]
  8. Bolooki H., Schwartzman R. J. High-dose steroids for perioperative management of patients with myasthenia gravis undergoing thymectomy. A preliminary report. J Thorac Cardiovasc Surg. 1978 May;75(5):754–757. [PubMed] [Google Scholar]
  9. Brenner T., Abramsky O., Lisak R. P., Zweiman B., Tarrab-Hazdai R., Fuchs S. Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients. Isr J Med Sci. 1978 Sep;14(9):986–989. [PubMed] [Google Scholar]
  10. Brunner N. G., Berger C. L., Namba T., Grob D. Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management. Ann N Y Acad Sci. 1976;274:577–595. doi: 10.1111/j.1749-6632.1976.tb47717.x. [DOI] [PubMed] [Google Scholar]
  11. Brunner N. G., Namba T., Grob D. Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. Neurology. 1972 Jun;22(6):603–610. doi: 10.1212/wnl.22.6.603. [DOI] [PubMed] [Google Scholar]
  12. Buckingham J. M., Howard F. M., Jr, Bernatz P. E., Payne W. S., Harrison E. G., Jr, O'Brien P. C., Weiland L. H. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg. 1976 Oct;184(4):453–458. doi: 10.1097/00000658-197610000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Calvey T. N., Chan K. Plasma pyridostigmine levels in patients with myasthenia gravis. Clin Pharmacol Ther. 1977 Feb;21(2):187–193. doi: 10.1002/cpt1977212187. [DOI] [PubMed] [Google Scholar]
  14. Chan K., Calvey T. N. Renal clearance of pyridostigmine in patients with myasthenia gravis. Eur Neurol. 1977;16(1-6):69–72. doi: 10.1159/000114882. [DOI] [PubMed] [Google Scholar]
  15. Cohan S. L., Dretchen K. L., Neal A. Malabsorption of pyridostigmine in patients with myasthenia gravis. Neurology. 1977 Mar;27(3):299–301. doi: 10.1212/wnl.27.3.299. [DOI] [PubMed] [Google Scholar]
  16. Cohan S. L., Pohlmann J. L., Mikszewski J., O'Doherty D. S. The pharmacokinetics of pyridostigmine. Neurology. 1976 Jun;26(6 Pt 1):536–539. doi: 10.1212/wnl.26.6.536. [DOI] [PubMed] [Google Scholar]
  17. Cohn H. E., Solit R. W., Schatz N. J., Schlezinger N. Surgical treatment in myasthenia gravis. A 27 year experience. J Thorac Cardiovasc Surg. 1974 Dec;68(6):876–885. [PubMed] [Google Scholar]
  18. Dau P. C., Lindstrom J. M., Cassel C. K., Denys E. H., Shev E. E., Spitler L. E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 1977 Nov 24;297(21):1134–1140. doi: 10.1056/NEJM197711242972102. [DOI] [PubMed] [Google Scholar]
  19. Drachman D. B. Myasthenia gravis (first of two parts). N Engl J Med. 1978 Jan 19;298(3):136–142. doi: 10.1056/NEJM197801192980305. [DOI] [PubMed] [Google Scholar]
  20. Dunn J. M. Neonatal myasthenia. Am J Obstet Gynecol. 1976 May 15;125(2):265–266. doi: 10.1016/0002-9378(76)90606-2. [DOI] [PubMed] [Google Scholar]
  21. Emeryk B., Strugalska M. H. Evaluation of results of thymectomy in myasthenia gravis. J Neurol. 1976 Jan 14;211(2):155–168. doi: 10.1007/BF00313359. [DOI] [PubMed] [Google Scholar]
  22. Engel A. G., Lambert E. H., Santa T. Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology. 1973 Dec;23(12):1273–1281. doi: 10.1212/wnl.23.12.1273. [DOI] [PubMed] [Google Scholar]
  23. Engel A. G., Santa T. Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann N Y Acad Sci. 1971 Sep 15;183:46–63. doi: 10.1111/j.1749-6632.1971.tb30741.x. [DOI] [PubMed] [Google Scholar]
  24. Engel W. K., Festoff B. W., Patten B. M., Swerdlow M. L., Newball H. H., Thompson M. D. Myasthenia gravis. Ann Intern Med. 1974 Aug;81(2):225–246. doi: 10.7326/0003-4819-81-2-225. [DOI] [PubMed] [Google Scholar]
  25. Farnsworth A., Pories W., Mendelsohn H. Thymectomy for myasthenia gravis. Aust N Z J Surg. 1976 May;46(2):170–173. doi: 10.1111/j.1445-2197.1976.tb03226.x. [DOI] [PubMed] [Google Scholar]
  26. Faulkner S. L., Ehyai A., Fisher R. D., Fenichel G. M., Bender H. W., Jr Contemporary management of myasthenia gravis: the clinical role of thymectomy. Ann Thorac Surg. 1977 Apr;23(4):348–352. doi: 10.1016/s0003-4975(10)64139-2. [DOI] [PubMed] [Google Scholar]
  27. Fineberg H. V., Hiatt H. H. Evaluation of medical practices. The case for technology assessment. N Engl J Med. 1979 Nov 15;301(20):1086–1091. doi: 10.1056/NEJM197911153012004. [DOI] [PubMed] [Google Scholar]
  28. Fischer K. C., Schwartzmann R. J. Oral corticosteroids in the treatment of ocular myasthenia gravis. Neurology. 1974 Aug;24(8):795–798. doi: 10.1212/wnl.24.8.795. [DOI] [PubMed] [Google Scholar]
  29. Fletcher R. H., Fletcher S. W. Clinical research in general medical journals: a 30-year perspective. N Engl J Med. 1979 Jul 26;301(4):180–183. doi: 10.1056/NEJM197907263010403. [DOI] [PubMed] [Google Scholar]
  30. Fonkalsrud E. W., Herrmann C., Jr, Mulder D. G. Thymectomy for myasthenia gravis in children. J Pediatr Surg. 1970 Apr;5(2):157–165. doi: 10.1016/0022-3468(70)90271-x. [DOI] [PubMed] [Google Scholar]
  31. Fraser K., Simpson J. A., Crawford J. The place of surgery in the treatment of myasthenia gravis. Br J Surg. 1978 May;65(5):301–304. doi: 10.1002/bjs.1800650503. [DOI] [PubMed] [Google Scholar]
  32. Fukuyama Y., Suzuki M., Segawa M. Studies on myasthenia gravis in childhood, especially on its clinical course and prognosis. Paediatr Univ Tokyo. 1970 Dec;18:57–68. [PubMed] [Google Scholar]
  33. GLASER G. H., MERRITT H. H. Effects of corticotropin (ACTH) and cortisone on disorders of the nervous system. J Am Med Assoc. 1952 Mar 15;148(11):898–904. doi: 10.1001/jama.1952.02930110020006. [DOI] [PubMed] [Google Scholar]
  34. GROB D. Course and management of myasthenia gravis. J Am Med Assoc. 1953 Oct 10;153(6):529–532. doi: 10.1001/jama.1953.02940230001001. [DOI] [PubMed] [Google Scholar]
  35. GROB D., HARVEY A. M. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp. 1952 Aug;91(2):124–136. [PubMed] [Google Scholar]
  36. Genkins G., Papatestas A. E., Horowitz S. H., Kornfield P. Studies in myasthenia gravis: early thymectomy. Electrophysiologic and pathologic correlations. Am J Med. 1975 Apr;58(4):517–524. doi: 10.1016/0002-9343(75)90125-4. [DOI] [PubMed] [Google Scholar]
  37. Goldman A. J., Herrmann C., Jr, Keesey J. C., Mulder D. G., Brown W. J. Myasthenia gravis and invasive thymoma: a 20-year experience. Neurology. 1975 Nov;25(11):1021–1025. doi: 10.1212/wnl.25.11.1021. [DOI] [PubMed] [Google Scholar]
  38. Grob D., Namba T. Corticotropin in generalized myasthenia gravis. Effect of short, intensive courses. JAMA. 1966 Nov 14;198(7):703–707. [PubMed] [Google Scholar]
  39. Gschnitzer F. Thymusexstirpation bei Myasthenia gravis. Z Erkr Atmungsorgane. 1975 Mar;142(3):284–289. [PubMed] [Google Scholar]
  40. Hofmann W. W. Antimyasthenic action of corticosteroids. Arch Neurol. 1977 Jun;34(6):356–360. doi: 10.1001/archneur.1977.00500180050010. [DOI] [PubMed] [Google Scholar]
  41. Horowitz S. H., Genkins G., Kornfeld P., Papatestas A. E. Regional curare test in evaluation of ocular myasthenia. Arch Neurol. 1975 Feb;32(2):84–88. doi: 10.1001/archneur.1975.00490440034004. [DOI] [PubMed] [Google Scholar]
  42. Howard F. M., Jr, Duane D. D., Lambert E. H., Daube J. R. Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci. 1976;274:596–607. doi: 10.1111/j.1749-6632.1976.tb47718.x. [DOI] [PubMed] [Google Scholar]
  43. Hudson C. S., Rash J. E., Tiedt T. N., Albuquerque E. X. Neostigmine-induced alterations at the mammalian neuromuscular junction. II. Ultrastructure. J Pharmacol Exp Ther. 1978 May;205(2):340–356. [PubMed] [Google Scholar]
  44. Jaretzki A., 3rd, Bethea M., Wolff M., Olarte M. R., Lovelace R. E., Penn A. S., Rowland L. A rational approach to total thymectomy in the treatment of myasthenia gravis. Ann Thorac Surg. 1977 Aug;24(2):120–130. doi: 10.1016/s0003-4975(10)63720-4. [DOI] [PubMed] [Google Scholar]
  45. Jenkins R. B. Treatment of myasthenia gravis with prednisone. Lancet. 1972 Apr 8;1(7754):765–767. doi: 10.1016/s0140-6736(72)90520-x. [DOI] [PubMed] [Google Scholar]
  46. Johns T. R., Howard F. M. Symposium on therapeutic controversies. Myasthenia gravis. Steroids and immunosuppressive drugs. Trans Am Neurol Assoc. 1978;103:278–281. [PubMed] [Google Scholar]
  47. Johns T. R., Howard F. M. Symposium on therapeutic controversies. Myasthenia gravis. Steroids and immunosuppressive drugs. Trans Am Neurol Assoc. 1978;103:278–281. [PubMed] [Google Scholar]
  48. Joseph B. S., Johns T. R. Recurrence of nonneoplastic thymus after thymectomy for myasthenia gravis. Report of two cases. Neurology. 1973 Feb;23(2):109–116. doi: 10.1212/wnl.23.2.109. [DOI] [PubMed] [Google Scholar]
  49. KEYNES G. Investigations into thymic disease and tumour formation. Br J Surg. 1955 Mar;42(175):449–462. doi: 10.1002/bjs.18004217502. [DOI] [PubMed] [Google Scholar]
  50. Kjaer M. Myasthenia gravis and myasthenic syndromes treated with prednisone. Acta Neurol Scand. 1971;47(4):464–474. doi: 10.1111/j.1600-0404.1971.tb07501.x. [DOI] [PubMed] [Google Scholar]
  51. Klingen G., Johansson L., Westerholm C. J., Sundstroöm C. Transcervical thymectomy with the aid of mediastinoscopy for myasthenia gravis: eight years' experience. Ann Thorac Surg. 1977 Apr;23(4):342–347. doi: 10.1016/s0003-4975(10)64138-0. [DOI] [PubMed] [Google Scholar]
  52. Kornfeld P., Genkins G., Papatestas A. E., Horowitz S. H. Steroid therapy in myasthenia gravis associated with thymoma. Mt Sinai J Med. 1978 Jan-Feb;45(1):106–115. [PubMed] [Google Scholar]
  53. Kornfeld P., Mittag T. N., Genkins G., Horowitz S., Papatestas A. E. Studies in myasthenia gravis. Pyridostigmine-C14 metabolism after thymectomy. Neurology. 1975 Oct;25(10):998–999. doi: 10.1212/wnl.25.10.998. [DOI] [PubMed] [Google Scholar]
  54. Lava N. S., Rodichok L., Martinez L. B. Recurrence of thymoma and myasthenia gravis after 19 years. A case report. Neurology. 1976 Jul;26(7):696–698. doi: 10.1212/wnl.26.7.696. [DOI] [PubMed] [Google Scholar]
  55. Le Brigand H., Leuasseur P., Merlier M., Rojas-Miranda A., Gaud C., Noviant Y. Cent thymectomies chez des myasthéniques. Résultats lointains. Rev Neurol (Paris) 1972 Apr;126(4):267–274. [PubMed] [Google Scholar]
  56. Leeuwin R. S., Wolters E. C. Effect of corticosteroids on sciatic nerve-tibialis anterior muscle of rats treated with hemicholinium-3. An experimental approach to a possible mechanism of action of corticosteroids in myasthenia gravis. Neurology. 1977 Feb;27(2):171–177. doi: 10.1212/wnl.27.2.171. [DOI] [PubMed] [Google Scholar]
  57. Leong A. S., Vignaendra V., Ghee L. T. A reappraisal of the significance of thymic germinal centers in myasthenia gravis. Eur Neurol. 1976;14(1):53–59. doi: 10.1159/000114726. [DOI] [PubMed] [Google Scholar]
  58. Leövey A., Szobor A., Szegedi G. y., Szathmáry I., Petrányi G. y. Myasthenia gravis: ALG treatment of seriously ill patients. Eur Neurol. 1975;13(5):422–432. doi: 10.1159/000114698. [DOI] [PubMed] [Google Scholar]
  59. Lindstrom J. M., Seybold M. E., Lennon V. A., Whittingham S., Duane D. D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976 Nov;26(11):1054–1059. doi: 10.1212/wnl.26.11.1054. [DOI] [PubMed] [Google Scholar]
  60. Lisak R. P., Schotland D. L. Symposium on therapeutic controversies. Myasthenia gravis. Plasmapheresis in the treatment of myasthenia gravis. Trans Am Neurol Assoc. 1978;103:292–302. [PubMed] [Google Scholar]
  61. MERRITT H. H. Corticotropin and cortisone in diseases of the nervous system. Yale J Biol Med. 1952 Jun;24(6):466–473. [PMC free article] [PubMed] [Google Scholar]
  62. MILLICHAP J. G., DODGE P. R. Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients. Neurology. 1960 Nov;10:1007–1014. doi: 10.1212/wnl.10.11.1007. [DOI] [PubMed] [Google Scholar]
  63. MILLIKAN C. H., EATON L. M. Clinical-evaluation of ACTH and cortisone in myasthenia gravis. Neurology. 1951 Mar-Apr;1(2):145–152. doi: 10.1212/wnl.1.3.145. [DOI] [PubMed] [Google Scholar]
  64. MOUNT F. W. CORTICOTROPIN IN TREATMENT OF OCULAR MYASTHENIA; A CONTROLLED CLINICAL TRIAL. Arch Neurol. 1964 Aug;11:114–124. doi: 10.1001/archneur.1964.00460200010002. [DOI] [PubMed] [Google Scholar]
  65. Masaoka A., Monden Y., Seike Y. Spontaneous remission of myasthenia gravis in patients with thymoma. Neurology. 1978 May;28(5):495–496. doi: 10.1212/wnl.28.5.495. [DOI] [PubMed] [Google Scholar]
  66. Masaoka A., Nagaoka Y., Kotake Y. Distribution of thymic tissue at the anterior mediastinum. Current procedures in thymectomy. J Thorac Cardiovasc Surg. 1975 Oct;70(4):747–754. [PubMed] [Google Scholar]
  67. Matell G., Bergström K., Franksson C., Hammarström L., Lefvert A. K., Möller E., von Reis G., Smith E. Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci. 1976;274:659–676. doi: 10.1111/j.1749-6632.1976.tb47724.x. [DOI] [PubMed] [Google Scholar]
  68. Mattila S., Pirskanen R., Heinonen J. Thymectomy for myasthenia gravis. Scand J Thorac Cardiovasc Surg. 1976;10(2):183–188. doi: 10.3109/14017437609167790. [DOI] [PubMed] [Google Scholar]
  69. McQuillen M. P., Leone M. G. A treatment carol: thymectomy revisited. Neurology. 1977 Dec;27(12):1103–1106. doi: 10.1212/wnl.27.12.1103. [DOI] [PubMed] [Google Scholar]
  70. Mendell J. R., Warmolts J. R., Bass J. C. Caution urged in childhood thymectomy for myasthenia gravis. Neurology. 1977 Dec;27(12):1182–1182. doi: 10.1212/wnl.27.12.1182. [DOI] [PubMed] [Google Scholar]
  71. Middleton G. The incidence of follicular structures in the human thymus at autopsy. Aust J Exp Biol Med Sci. 1967 Apr;45(2):189–199. doi: 10.1038/icb.1967.14. [DOI] [PubMed] [Google Scholar]
  72. Mink J. H., Bein M. E., Sukov R., Herrmann C., Jr, Winter J., Sample W. F., Mulder D. Computer tomography of the anterior mediastinum in patients with myasthenia gravis and suspected thymoma. AJR Am J Roentgenol. 1978 Feb;130(2):239–246. doi: 10.2214/ajr.130.2.239. [DOI] [PubMed] [Google Scholar]
  73. Mulder D. G., Herrmann C., Buckberg G. D. Effect of thymectomy in patients with myasthenia gravis. A sixteen year experience. Am J Surg. 1974 Aug;128(2):202–206. [PubMed] [Google Scholar]
  74. NASTUK W. L., PLESCIA O. J., OSSERMAN K. E. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med. 1960 Oct;105:177–184. doi: 10.3181/00379727-105-26050. [DOI] [PubMed] [Google Scholar]
  75. Namba T., Brunner N. G., Grob D. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine (Baltimore) 1978 Sep;57(5):411–433. doi: 10.1097/00005792-197809000-00002. [DOI] [PubMed] [Google Scholar]
  76. Newsom-Davis J., Pinching A. J., Vincent A., Wilson S. G. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology. 1978 Mar;28(3):266–272. doi: 10.1212/wnl.28.3.266. [DOI] [PubMed] [Google Scholar]
  77. Newsom-Davis J., Wilson S. G., Vincent A., Ward C. D. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet. 1979 Mar 3;1(8114):464–468. doi: 10.1016/s0140-6736(79)90823-7. [DOI] [PubMed] [Google Scholar]
  78. Osserman K. E., Genkins G. Studies in myasthenia gravis. Short-term massive corticotropin therapy. JAMA. 1966 Nov 14;198(7):699–702. [PubMed] [Google Scholar]
  79. Papatestas A. E., Alpert L. I., Osserman K. E., Osserman R. S., Kark A. E. Studies in myasthenia gravis: effects of thymectomy. Results on 185 patients with nonthymomatous and thymomatous myasthenia gravis, 1941-1969. Am J Med. 1971 Apr;50(4):465–474. doi: 10.1016/0002-9343(71)90336-6. [DOI] [PubMed] [Google Scholar]
  80. Papatestas A. E., Genkins G., Jaretzki A. Symposium on therapeutic controversies. Myasthenia gravis. Cervical thymectomy. Trans Am Neurol Assoc. 1978;103:286–291. [PubMed] [Google Scholar]
  81. Papatestas A. E., Genkins G., Kornfeld P., Horowitz S., Kark A. E. Transcervical thymectomy in myasthenia gravis. Surg Gynecol Obstet. 1975 Apr;140(4):535–540. [PubMed] [Google Scholar]
  82. Patten B. M., Oliver K. L., Engel W. K. Adverse interaction between steroid hormones and anticholinesterase drugs. Neurology. 1974 May;24(5):442–449. doi: 10.1212/wnl.24.5.442. [DOI] [PubMed] [Google Scholar]
  83. Perlo V. P., Arnason B., Castleman B. The thymus gland in elderly patients with myasthenia gravis. Neurology. 1975 Mar;25(3):294–295. doi: 10.1212/wnl.25.3.294. [DOI] [PubMed] [Google Scholar]
  84. Perlo V. P., McQuillen M. P. Symposium on therapeutic controversies. Myasthenia gravis. Thymectomy. Trans Am Neurol Assoc. 1978;103:282–285. [PubMed] [Google Scholar]
  85. Pinching A. J., Peters D. K. Remission of myasthenia gravis following plasma-exchange. Lancet. 1976 Dec 25;2(8000):1373–1376. doi: 10.1016/s0140-6736(76)91917-6. [DOI] [PubMed] [Google Scholar]
  86. Pinelli P., Tonali P., Scoppetta C. Long-term treatment of myasthenia gravis with alternate-day prednisone. Report on 15 patients. Eur Neurol. 1974;12(3):129–141. doi: 10.1159/000114612. [DOI] [PubMed] [Google Scholar]
  87. Pirofsky B., Reid R. H., Bardana E. J., Jr, Baker R. L. Myasthenia gravis treated with purified antithymocyte antiserum. Neurology. 1979 Jan;29(1):112–116. doi: 10.1212/wnl.29.1.112. [DOI] [PubMed] [Google Scholar]
  88. ROWLAND L. P., ARANOW H., Jr, HOEFER P. F. Myasthenia gravis appearing after the removal of thymoma. Neurology. 1957 Aug;7(8):584–588. doi: 10.1212/wnl.7.8.584. [DOI] [PubMed] [Google Scholar]
  89. ROWLAND L. P., HOEFER P. F., ARANOW H., Jr, MERRITT H. H. Fatalities in myasthenia gravis; a review of 39 cases with 26 autopsies. Neurology. 1956 May;6(5):307–326. doi: 10.1212/wnl.6.5.307. [DOI] [PubMed] [Google Scholar]
  90. ROWLAND L. P., KORENGOLD M. C., JAFFE I. A., BERG L., SHY G. M. Prostigmine-induced muscle weakness in myasthenia gravis patients. Neurology. 1955 Feb;5(2):89–99. doi: 10.1212/wnl.5.2.89. [DOI] [PubMed] [Google Scholar]
  91. Rowland L. P. Immunosuppressive drugs in treatment of myasthenia gravis. Ann N Y Acad Sci. 1971 Sep 15;183:351–357. doi: 10.1111/j.1749-6632.1971.tb30764.x. [DOI] [PubMed] [Google Scholar]
  92. Ryniewicz B., Badurska B. Follow-up study of myasthenic children after thymectomy. J Neurol. 1977 Dec 13;217(2):133–138. doi: 10.1007/BF00312926. [DOI] [PubMed] [Google Scholar]
  93. SCHLEZINGER N. S. Present status of therapy in myasthenia gravis. J Am Med Assoc. 1952 Feb 16;148(7):508–513. doi: 10.1001/jama.1952.02930070008003. [DOI] [PubMed] [Google Scholar]
  94. SIMPSON J. A. An evaluation of thymectomy in myasthenia gravis. Brain. 1958 Mar;81(1):112–144. doi: 10.1093/brain/81.1.112. [DOI] [PubMed] [Google Scholar]
  95. Sambrook M. A., Reid H., Mohr P. D., Boddie H. G. Myasthenia gravis: clinical and histological features in relation to thymectomy. J Neurol Neurosurg Psychiatry. 1976 Jan;39(1):38–43. doi: 10.1136/jnnp.39.1.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Sarnat H. B., McGarry J. D., Lewis J. E., Jr Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy. Neurology. 1977 Jun;27(6):550–553. doi: 10.1212/wnl.27.6.550. [DOI] [PubMed] [Google Scholar]
  97. Schwartz M. S., Sargeant M. K., Swash M. Neostigmine-induced end-plate proliferation in the rat. A study using supra-vital methylene blue. Neurology. 1977 Mar;27(3):289–293. doi: 10.1212/wnl.27.3.289. [DOI] [PubMed] [Google Scholar]
  98. Seybold M. E., Drachman D. B. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med. 1974 Jan 10;290(2):81–84. doi: 10.1056/NEJM197401102900204. [DOI] [PubMed] [Google Scholar]
  99. Seybold M. E., Howard F. M., Jr, Duane D. D., Payne W. S., Harrison E. G., Jr Thymectomy in juvenile myasthenia gravis. Arch Neurol. 1971 Nov;25(5):385–392. doi: 10.1001/archneur.1971.00490050019001. [DOI] [PubMed] [Google Scholar]
  100. Simpson J. A. A morphological explanation of the transmission defect in myasthenia gravis. Ann N Y Acad Sci. 1971 Sep 15;183:241–247. doi: 10.1111/j.1749-6632.1971.tb30755.x. [DOI] [PubMed] [Google Scholar]
  101. Strand F. L., Stoboy H., Friedebold, Krivoy, Heyck, van Riezen Letter: Effect of A.C.T.H. petide fragment on muscle action-potentials. Lancet. 1975 Nov 8;2(7941):919–919. doi: 10.1016/s0140-6736(75)92150-9. [DOI] [PubMed] [Google Scholar]
  102. Swaiman K. F., Varco R. L. Thymectomy. In fulminating myasthenia gravis of childhood. Minn Med. 1972 Sep;55(9):809–810. [PubMed] [Google Scholar]
  103. Szobor A., Petrányi G. Immunosuppressive therapy of myasthenia gravis. Acta Med Acad Sci Hung. 1970;27(4):397–411. [PubMed] [Google Scholar]
  104. TORDA C., WOLFF H. G. Effects of administration of the adrenocorticotropic hormone on patients with myasthenia gravis. AMA Arch Neurol Psychiatry. 1951 Aug;66(2):163–170. doi: 10.1001/archneurpsyc.1951.02320080047004. [DOI] [PubMed] [Google Scholar]
  105. Takahashi M., Kang J., Takeuchi H., Tarui S., Nishikawa M., Masaoka A., Monden Y. Evaluation of the effect of thymectomy in myasthenia gravis. Med J Osaka Univ. 1978 Dec;29(3-4):281–286. [PubMed] [Google Scholar]
  106. Torda C., Wolff H. G. EFFECTS OF ADRENOCORTICOTROPHIC HORMONE ON NEURO-MUSCULAR FUNCTION IN PATIENTS WITH MYASTHENIA GRAVIS. J Clin Invest. 1949 Sep;28(5 Pt 2):1228–1235. doi: 10.1172/JCI102157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Twomey J. J., Lewis V. M., Patten B. M., Goldstein G., Good R. A. Myasthenia gravis, thymectomy and serum thymic hormone activity. Am J Med. 1979 Apr;66(4):639–643. doi: 10.1016/0002-9343(79)91175-6. [DOI] [PubMed] [Google Scholar]
  108. Vetters J. M., Simpson J. A. Comparison of thymic histology with response to thymectomy in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1974 Oct;37(10):1139–1145. doi: 10.1136/jnnp.37.10.1139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Vincent A., Newsom-Davis J. Absence of anti-acetylcholine receptor antibodies in congenital myasthenia gravis. Lancet. 1979 Feb 24;1(8113):441–442. doi: 10.1016/s0140-6736(79)90918-8. [DOI] [PubMed] [Google Scholar]
  110. Ward M. D., Forbes M. S., Johns T. R. Neostigmine methylsulfate. Does it have a chronic effect as well as a transient one? Arch Neurol. 1975 Dec;32(12):808–813. doi: 10.1001/archneur.1975.00490540052006. [DOI] [PubMed] [Google Scholar]
  111. Warmolts J. R., Engel W. K. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med. 1972 Jan 6;286(1):17–20. doi: 10.1056/NEJM197201062860104. [DOI] [PubMed] [Google Scholar]
  112. Wilson R. W., Ward M. D., Johns T. R. Corticosteroids: a direct effect at the neuromuscular junction. Neurology. 1974 Nov;24(11):1091–1095. doi: 10.1212/wnl.24.11.1091. [DOI] [PubMed] [Google Scholar]
  113. Wolters M. J., Leeuwin R. S. Effect of corticosteroids on the phrenic nerve-diaphragm of preparation treated with hemicholinium. A possible model of myasthenia gravis. Neurology. 1976 Jun;26(6 Pt 1):574–578. doi: 10.1212/wnl.26.6.574. [DOI] [PubMed] [Google Scholar]
  114. von Reis G., Liljestrand A., Matell G. Treatment of severe myasthenia gravis with large doses of ACTH. Ann N Y Acad Sci. 1966 Jan 26;135(1):409–416. doi: 10.1111/j.1749-6632.1966.tb45487.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES